Differential and region-specific activation of mitogen-activated protein kinases following chronic administration of phencyclidine in rat brain.
S V Kyosseva, S M Owens, A D Elbein, C N Karson
Neuropsychopharmacology March 1, 2001 DOI: 10.1016/s0893-133x(00)00180-9 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal experiment Peer reviewed |
|---|---|
| Population | Rats |
| Intervention | Phencyclidine (PCP) |
| Dose | 18 mg/kg/day for time-course; 2.5, 10, 18, or 25 mg/kg/day for dose-response |
| Duration | 3, 10, or 20 days for time course; 10 days for dose-response |
| Measures | Western blot analysis of phosphorylated ERK1, ERK2, MEK, JNK, and p38 |
| Key findings | Chronic PCP infusion produced a time- and dose-dependent increase in ERK1 and ERK2 phosphorylation specifically in the cerebellum, with no changes in JNK or p38 activity. |
Abstract
We have previously demonstrated elevation of the extracellular signal-regulated kinase (ERK) pathway in the cerebellum from patients with schizophrenia, an illness that may involve dysfunction of the N-methyl-D-aspartate (NMDA) receptor. Since the NMDA antagonist, phencyclidine (PCP), produces schizophrenic-like symptoms in humans, and abnormal behavior in animals, we examined the effects of chronic PCP administration in time- and dose-dependent manner on ERK and two other members of mitogen-activated protein kinase family, c-Jun N-terminal protein kinase (JNK) and p38, in rat brain. Osmotic pumps for PCP (18 mg/kg/day) and saline (controls) were implanted subcutaneously in rats for three, 10, and 20 days. Using Western blot analysis, we found no change at three days, but a significant increase in the phosphorylation of ERK1, ERK2 and MEK in the cerebellum at 10- and 20-days of continuous PCP infusion. For the experiments involving various doses of PCP, rats were infused with PCP at concentrations of 2.5, 10, 18, or 25 mg/kg/day, or saline for 10 days. We observed a dose-dependent elevation in the phosphorylation of ERK1 and ERK2 only in the cerebellum but not in brainstem, frontal cortex or hippocampus. The activities of JNK and p38 were unchanged in all investigated brain regions including cerebellum. These results demonstrate that chronic infusion of PCP in rats produces a differential and brain region-specific activation of MAP kinases, suggesting a role for the ERK signaling pathway in PCP abuse and perhaps in schizophrenia.
Citations in the library
Cited by 3
- Discriminative Stimulus Effects of Hallucinogenic Drugs: a Possible Relation to Reinforcing and Aversive Effects Journal of Pharmacological Sciences June 12, 2019
- The Discriminative Stimulus Properties of Hallucinogenic and Dissociative Anesthetic Drugs. Current Topics in Behavioral Neurosciences 2018
- Reduced activation of intracellular signaling pathways in rat prefrontal cortex after chronic phencyclidine administration. Pharmacological Research April 2008
Cites 4
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Reviews in the Neurosciences 1999
- A Review of NMDA Receptors and the Phencyclidine Model of Schizophrenia Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy January 2, 1996
- The PCP site of the NMDA receptor complex. Advances in experimental medicine and biology 1990